FASTCURE: a consortium of experts to respond to the epidemic COVID-19 coronavirus outbreak

Home - News - FASTCURE: a consortium of experts to respond to the epidemic COVID-19 coronavirus outbreak

FASTCURE: a consortium of experts to respond to the epidemic COVID-19 coronavirus outbreak

FASTCURE is a consortium of experts for screening, identification and formulation of chemical compounds to combat SARS-CoV-2.

Drug repurposing can be a key strategy to fight against pathogens, especially when it comes as a rapid response to an emerging pathogen such as SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) identified in Wuhan, China in January 2020, responsible for a worldwide pandemic, as declared by WHO on 11th March 2020.

On the initiative of Innophore (Enzyme & Drug Discovery Catalophore platform), University of Graz and acib (the Austrian Centre of Industrial Biotechnology), academics and industries from whom Adjuvatis, were gathered within the FASTCURE consortium, offering a set of expertise to counter the COVID-19 epidemic wave.

FASTCURE consortium aims to rapidly identify, collect and verify chemical compounds and methods suitable for inhibiting SARS-CoV-2 (formerly known as 2019-nCoV) Mpro protease as a primary target.

ADJUVATIS is at your side by developing adapted formulations for new efficient medical treatments. Contact us for support!